THERAPY DOSSIER · th-f2878735b53a

Mono-PEGylated human glucagon-like peptide-2 (Mono-PEG-hGLP-2), 5 kDa mPEG-SPA conjugate

Hormone

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 10

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT05181150 ↗Injury indicationNAunknown

Gut Peptides and Bone Remodeling in Individuals With Spinal Cord Injury

Spinal Cord Injuries

Enrolment: 20 · Results not recorded

NCT02099084 ↗PHASE4completed

Acute Effects of a Glucagon-like Peptide 2 Analog, Teduglutide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition

Short Bowel Syndrome

Enrolment: 8 · Results not recorded

NCT03860688 ↗PHASE2/PHASE3unknown

Investigating the Plasma Lipoprotein Response to a Single Subcutaneous Injection of Analogue Glucagon-like Peptide-2 and Oral Glucose in Humans

Hyperlipidemias

Enrolment: 15 · Results not recorded

NCT07704047 ↗PHASE2recruiting

Phase IIa Study of Recombinant Acylated Glucagon Like Peptide-2 Analog (FT1) for Injection in Patients With Short Bowel Syndrome

Short Bowel Syndrome · SBS

Enrolment: 8 · Results not recorded

NCT01573286 ↗PHASE1/PHASE2terminated

Phase 1-2 Trial of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure

Intestinal Failure · Short Bowel Syndrome

Enrolment: 13 · Results not recorded

NCT03682172 ↗EARLY_PHASE1completed

Effect of Glucagon-like Peptide 2 on Postprandial Gallbladder Motility in Healthy Subjects

Effect of Glucagon-like Peptide 2 on Gallbladder Motility

Enrolment: 15 · Results not recorded

NCT03859323 ↗PHASE1completed

Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of SHP681 (GLP-2 Analog-Fc Fusion) in Healthy Adult Subjects

Healthy Volunteers

Enrolment: 104 · Results not recorded

NCT06774807 ↗NAcompleted

Antagonist of the Glucagon-like Peptide 2 (GLP-2) Receptor

Healthy

Enrolment: 10 · Results not recorded

NCT00673751 ↗NAunknown

GLP-2 Mediated Increased SMA Blood Flow in Patients With Short Bowel Syndrome

Short Bowel Syndrome

Enrolment: 8 · Results not recorded

NCT03728959 ↗NAcompleted

Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism (KS-4-HypoPT)

Hypoparathyroidism

Enrolment: 7 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30247656 ↗2019Reported benefit

Purified PEGylated human glucagon-like peptide-2 reduces the severity of irradiation-induced acute radiation enteritis in rats.

RatRadiationSprague-DawleyMalen = 60 adult male rats randomised into six groupsIntraperitoneal injection3 microgram (low), 10 microgram (middle) and 30 microgram (…Described as pretreatment, although methods state irradiated rats recovered fro…

Model: Single 8 Gy abdominopelvic X-ray irradiation producing acute radiation enteritis, delivered at 0.74 Gy/min with the rest of the body shielded

Mono-PEG-hGLP-2 resisted DPP-IV degradation (26.7% intact at 1 h versus 5% for unmodified GLP-2) and dose-dependently preserved villus number and height and crypt height (villus height 507.9 +/- 21.1 micrometre at 30 microgram versus 233.1 +/- 14.8 micrometre in irradiated controls and 543.1 +/- 26…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…